Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy

被引：17

作者：

Kudo, Kazuko ^{[1
]}

Hama, Asahito ^{[2
]}

Kojima, Seiji ^{[2
]}

Ishii, Ruriko ^{[3
]}

Morimoto, Akira ^{[4
]}

Bessho, Fumio ^{[5
]}

Sunami, Shosuke ^{[6
]}

Kobayashi, Naoyuki ^{[7
]}

Kinoshita, Akitoshi ^{[8
]}

Okimoto, Yuri ^{[9
]}

Tawa, Akio ^{[10
]}

Tsukimoto, Ichiro ^{[11
]}

机构：

[1] Shizuoka Childrens Hosp, Div Hematol & Oncol, Aoi Ku, Shizuoka 4208660, Japan

[2] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi 4648601, Japan

[3] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 602, Japan

[4] Jichi Med Univ, Sch Med, Dept Pediat, Shimotsuke, Japan

[5] Kyorin Univ, Dept Pediat, Mitaka, Tokyo, Japan

[6] Narita Red Cross Hosp, Div Pediat, Narita, Japan

[7] Jikei Univ, Div Pediat, Kashiwa, Chiba, Japan

[8] St Marianna Univ, Sch Med, Dept Pediat, Kawasaki, Kanagawa, Japan

[9] Chiba Childrens Hosp, Div Hematol Oncol, Chiba, Japan

[10] Natl Hosp Org Osaka Hosp, Dept Pediat, Osaka, Japan

[11] Yokohama Tobu Hosp, Div Pediat, Yokohama, Kanagawa, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2010年 / 91卷 / 04期

关键词：

Acute megakaryoblastic leukemia; Mosaic Down syndrome; Cytarabine; GATA1; COOPERATIVE-STUDY GROUP; OF-THE-LITERATURE; DOWN-SYNDROME; MEGAKARYOBLASTIC LEUKEMIA; TRANSIENT LEUKEMIA; GATA1; MUTATION; CHILDREN; AML; TRISOMY-21; INTENSITY;

D O I：

10.1007/s12185-010-0549-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The present study aimed to identify optimal treatment intensity in children with mosaic Down syndrome (DS) and acute megakaryoblastic leukemia (AMKL). A retrospective review of AMKL patients was undertaken to identify mosaic DS children. Between November 1992 and November 2007, seven children were diagnosed as mosaic DS and AMKL. The median age at diagnosis was 29 months (range 4-34 months). Three patients had a past history of transient abnormal myelopoiesis. UPN1-4 were treated with intermediate-dose cytarabine and UPN4 received additional one course of high-dose cytarabine. All of these patients were remained in first CR. UPN5-7 were treated with high-dose cytarabine according to the AML99 protocol. UPN5 with GATA1 mutation suffered from acute pneumonia and pancreatitis and discontinued chemotherapy. UPN7 relapsed after cessation of chemotherapy and was rescued with allo-PBSCT. The cumulative doses of cytarabine were 3.5-10.65 g/m(2) in the UPN1-4 and 40.4-78.4 g/m(2) in the UPN5-7. The 8-year overall survival was 100% and the 8-year event-free survival 85.7%, respectively. Our retrospective study reveals that patients with mosaic DS and AMKL have a good prognosis. Reduction in intensity may work in patients with mosaic DS as well as with AML-DS.

引用

页码：630 / 635

页数：6

共 50 条

[21] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia [J].

Amy Y. Wang ;

Howard Weiner ;

Margaret Green ;

Hua Chang ;

Noreen Fulton ;

Richard A. Larson ;

Olatoyosi Odenike ;

Andrew S. Artz ;

Michael R. Bishop ;

Lucy A. Godley ;

Michael J. Thirman ;

Satyajit Kosuri ;

Jane E. Churpek ;

Emily Curran ;

Kristen Pettit ;

Wendy Stock ;

Hongtao Liu .

Journal of Hematology & Oncology, 11

[22] Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome [J].

Shadman, Mazyar ;

Mawad, Raya ;

Dean, Carol ;

Chen, Tara L. ;

Shannon-Dorcy, Kathleen ;

Sandhu, Vicky ;

Hendrie, Paul C. ;

Scott, Bart L. ;

Walter, Rol B. ;

Becker, Pamela S. ;

Pagel, John M. ;

Estey, Elihu H. .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) :483-486

[23] Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction [J].

Barker, Jacob A. ;

Marini, Bernard L. ;

Bixby, Dale ;

Perissinotti, Anthony J. .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (06) :811-815

[24] Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy [J].

Amaki, Jun ;

Onizuka, Makoto ;

Ohmachi, Ken ;

Aoyama, Yasuyuki ;

Hara, Ryujiro ;

Ichiki, Akifumi ;

Kawai, Hidetsugu ;

Sato, Ai ;

Miyamoto, Mitsuki ;

Toyosaki, Masako ;

Machida, Shinichiro ;

Kojima, Minoru ;

Shirasugi, Yukari ;

Kawada, Hiroshi ;

Ogawa, Yoshiaki ;

Ando, Kiyoshi .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) :543-553

[25] Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy [J].

Jun Amaki ;

Makoto Onizuka ;

Ken Ohmachi ;

Yasuyuki Aoyama ;

Ryujiro Hara ;

Akifumi Ichiki ;

Hidetsugu Kawai ;

Ai Sato ;

Mitsuki Miyamoto ;

Masako Toyosaki ;

Shinichiro Machida ;

Minoru Kojima ;

Yukari Shirasugi ;

Hiroshi Kawada ;

Yoshiaki Ogawa ;

Kiyoshi Ando .

International Journal of Hematology, 2015, 101 :543-553

[26] Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study [J].

Yue-ying Mao ;

Hua-cong Cai ;

Kai-ni Shen ;

Chang, Long ;

Zhang, Lu ;

Zhang, Yan ;

Feng, Jun ;

Wang, Wei ;

Yang, Chen ;

Tie-nan Zhu ;

Ming-hui Duan ;

Dao-bin Zhou ;

Xin-xin Cao ;

Li, Jian .

ANNALS OF HEMATOLOGY, 2022, 101 (04) :831-836

[27] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine [J].

Arana-Yi, Cecilia ;

Block, AnneMarie W. ;

Sait, Sheila N. ;

Ford, Laurie A. ;

Barcos, Maurice ;

Baer, Maria R. .

LEUKEMIA RESEARCH, 2008, 32 (07) :1043-1048

[28] Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy [J].

Huetter-Kroenke, Marie-Luise ;

Benner, Axel ;

Doehner, Konstanze ;

Krauter, Juergen ;

Weber, Daniela ;

Moessner, Margit ;

Koehne, Claus-Henning ;

Horst, Heinz A. ;

Schmidt-Wolf, Ingo G. H. ;

Rummel, Mathias ;

Goetze, Katharina ;

Koller, Elisabeth ;

Petzer, Andreas L. ;

Salwender, Hans ;

Fiedler, Walter ;

Kirchen, Heinz ;

Haase, Detlef ;

Kremers, Stephan ;

Theobald, Matthias ;

Matzdorff, Axel C. ;

Ganser, Arnold ;

Doehner, Hartmut ;

Schlenk, Richard F. .

HAEMATOLOGICA, 2016, 101 (07) :839-845

[29] Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study [J].

Zhou, Wei ;

Chen, Guofeng ;

Gong, Dan ;

Li, Yan ;

Huang, Sai ;

Wang, Nan ;

Xu, Qingyu ;

Xiong, Qian ;

Jing, Yu ;

Lv, Na ;

Wang, Lili ;

Li, Yonghui ;

Yu, Li .

LEUKEMIA & LYMPHOMA, 2020, 61 (04) :820-830

[30] Standard-Intensity Induction and Intermediate/ High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study [J].

Wang, Li ;

Zhao, Na ;

Zhou, Li ;

Tong, Juan ;

Xue, Lei ;

Zhang, Lei ;

Han, Yongsheng ;

Wang, Xingbing ;

Geng, Liangquan ;

Tang, Baolin ;

Liu, Huilan ;

Zhu, Weibo ;

Cai, Xiaoyan ;

Liu, Xin ;

Zhu, Xiaoyu ;

Sun, Zimin ;

Zheng, Changcheng .

CLINICAL INTERVENTIONS IN AGING, 2022, 17 :55-64

← 1 2 3 4 5 →